Kezdőlap・Részvénylista・Vir Biotechnology Inc

Vir Biotechnology Inc

Lezárt

SzektorEgészségügy

9.08 0.55

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

8.8

Maximum

9.08

Fő mutatók
By Trading Economics
Bevétel	80M -46M
Értékesítés	239M 239M
Egy részvényre jutó nyereség	0.47
Profit margin	-19.09
Munkavállalók	367
EBITDA	201M 78M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+137.61% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. nov. 4.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	3.3M 1.5B
Előző nyitás	8.53
Előző zárás	9.08

Hangulat hírek alapján

By Acuity

20%

80%

32 / 340 Rangsor szerint Healthcare

Vir Biotechnology Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 11. 19:36 UTC

Vir Biotechnology Inc. shares are trading roughly flat amid geopolitical tensions and anticipation of U.S. inflation reports that could influence Federal Reserve policy.

2026. aug. 10. 23:56 UTC

Vir Biotechnology Inc. shares advanced in after-market trading, reflecting a modest increase from Monday's close, though still below the 20-day moving average.

2026. aug. 7. 19:36 UTC

Correlated Moves

Vir Biotechnology shares are higher, supported by broader market gains and a notable increase in the ARK Genomic Revolution ETF.

2026. aug. 6. 23:21 UTC

Vir Biotechnology Inc shares are higher in after-market trading, showing positive momentum following Thursday's close. No specific news was identified to explain the movement.

2026. aug. 5. 23:41 UTC

News

Social Media

Vir Biotechnology reported second-quarter revenue of $238.9 million, exceeding estimates, contributing to significant gains in after-market trading.

2026. aug. 3. 19:46 UTC

Vir Biotechnology Inc's shares are higher today, reflecting broader market trends amid falling oil prices. The stock remains below its 20-day moving average.

2026. júl. 30. 19:58 UTC

Vir Biotechnology Inc shares are higher today amid a broader recovery in tech stocks, despite breaking a recent trend of higher daily closes.

2026. júl. 29. 19:27 UTC

Shares of Vir Biotechnology Inc. are trading lower today, having declined after an initial uptick and hitting a session low in late morning.

2026. júl. 28. 15:46 UTC

Correlated Moves

Shares lower today, pressured by declines in biotech sector.

2026. júl. 27. 20:07 UTC

Vir Biotechnology's shares are higher today, continuing gains since Friday. The broader market is influenced by declining oil prices and lower Treasury yields.

2026. júl. 25. 00:01 UTC

Vir Biotechnology Inc shares are higher in after-market trading, recovering from earlier lows. The stock is near the lower end of its one-month trading range.

2026. júl. 24. 23:31 UTC

Vir Biotechnology Inc shares are higher in after-market trading, reflecting notable gains since Friday's close, despite no specific news driving the price action.

2026. júl. 21. 17:16 UTC

Correlated Moves

Vir Biotechnology Inc's shares are higher today, supported by a positive trend in the broader biotech sector. Earlier, shares pulled back but have since recovered.

2026. júl. 20. 21:02 UTC

Vir Biotechnology Inc shares fell during after-market hours amid broader market declines following a reported drop in the Leading Economic Index for June.

Társak összehasonlítása

Árváltozás

Vir Biotechnology Inc Előrejelzés

Célár

By TipRanks

137.61% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 21.29 USD 137.61%

Magas 30 USD

Alacsony 15 USD

8 Wall Street elemző 12 hónapos célárain alapulva a(z)Vir Biotechnology Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

8 ratings

Vétel

Tartás

Eladás

8 Wall Street elemző célárain alapulva a(z)Vir Biotechnology Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

32 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.